london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


The aflibercept action in registrant to treat AMD cases

Poster Details

First Author: G.Pappas GREECE

Co Author(s):    A. Agelakis   G. Bastakis               0   0 0   0 0   0 0   0 0

Abstract Details


To evaluate the efficacy of Aflibercept in AMD cases where Rnibizumab and Bevacizumab were unsuccessful to treat


Venizeleio Hospital of Heraklion


We collected the data of 24 AMD cases, previously treated unsuccessfully ( Central Macular Thickness 382.8+/- 55.1 μm) with Ranibizumab and Bevacizumab. We excluded the possibility of RAP or PCV. We evaluated the Central Macular Thickness (OPKO OCT) and the final visual acuity ( ETDRS chart). The follow up period was 6 months.


There was a statistical significant 50.7 μm reduction in CMT, p< 0.01. There was a 3 letters increase in Visual Acuity


Aflibercept may treat cases of AMD where Ranibizumab and Bevacizumab were unable to treat

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy